Answer
Yes, visual disturbances have occurred with lorlatinib; patients should report any visual symptoms, and new or worsening severe symptoms warrant consideration of an ophthalmologic evaluation and dose reduction.
Sources for this answer
- Lorviqua 25 mg film coated tablets,Pfizer Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 14Document updated
Sources checked